NCT03937141

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Chinook Therapeutics, Inc. (formerly Aduro) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. The population will consist of adults with PD-L1 positive recurrent or metastatic HNSCC.

Conditions

• Metastatic Head and Neck Cancer
• Recurrent Head and Neck Cancer

Interventions

Type	Name	Description
DRUG	ADU-S100	intratumoral

Timeline

• Start date: 2019-08-26
• Primary completion: 2021-05-10
• Completion: 2021-06-10
• First posted: 2019-05-03
• Last updated: 2022-01-03
• Results posted: 2022-01-03

Locations

17 sites across 1 country: United States

Regulatory

• FDA-regulated drug study